MyRisk® Hereditary Cancer Test with RiskScore® now incorporates breast density using TCv8 to provide patients & providers with a more comprehensive look at their five-year and remaining lifetime risk for #breastcancer. Learn more: https://t.co/JKJRr5WoQP
📢#HereditaryLive is happening tomorrow. Still time to add tomorrow's date to your🗓️
🧬June 15 👉https://t.co/0iqkbobZYR
🚨Add the other dates too🚨
🧬Aug 17 👉https://t.co/8N74HVoqTd
🧬Oct 19👉https://t.co/yltrrea27z
🧬Dec 21 👉https://t.co/02qWtBGoyt
#HereditaryGICancer
“Chicago is my kind of town” according to Frank S. But my time at #ASCO23 is over but @myriadgenetics will be at booth 4063 so please stop by and see the new Myriad! Remember to count your #Ascosteps! @myriadgenetics
One more day at #ASCO23 I won’t be at booth #4063 to introduce you to the new @myriadgenetics but step on over and my friends will update you #Ascosteps
Does anyone else LOVE the shuttle ride back to the hotels after a long day at #ASCO23? Almost feels cathartic. Last day of exhibits tomorrow!
@myriadgenetics
At #ASCO23, our mission to advance cancer care for all is front and center. Learn more from Michael Lyons, general manager of Oncology at Myriad, and visit us at booth #4063.
📢@ASCO members ‼️
➡️the experts from the multidisciplinary #HereditaryGICancer community are at #ASCO2023 presenting at various sessions https://t.co/yCAGBaQN7j
➡️Take a listen & learn more abt what is happening in this field. Good opportunity to ask your ❓
Lights, Camera, Action! 📸
Michael Lyons, president of #Oncology at Myriad, shares insights on our progress in our Oncology commitment.
Stop by booth #4063 and read Michael’s @LinkedIn blog to learn more: https://t.co/TWBddvsjPO #ASCO23